Summary by Moomoo AI
Thermo Fisher Scientific reported Q2 2024 revenue of $10.54 billion, down 1% year-over-year. GAAP EPS increased 15% to $4.04, while adjusted EPS rose 4% to $5.37. The company's core organic revenue growth was flat, excluding COVID-19 testing impacts.Thermo Fisher launched several innovative products during the quarter, including new mass spectrometers and sustainable bioprocessing solutions. The company also expanded its clinical trial supply services and global presence.Based on strong first-half performance, Thermo Fisher raised its full-year 2024 guidance. Revenue is now expected to be $42.4-$43.3 billion, up from $42.3-$43.3 billion previously. Adjusted EPS guidance was increased to $21.29-$22.07, compared to $21.14-$22.02 earlier. The company also completed its acquisition of Olink, enhancing its proteomics capabilities.
